<DOC>
	<DOCNO>NCT02608034</DOCNO>
	<brief_summary>This two-part , Phase 1 , open-label , multicenter , two-period , one-sequence study investigate effect itraconazole rifampin PK vemurafenib follow multiple 960 milligram ( mg ) twice daily ( BID ) dose adult participant unresectable Stage IIIC Stage IV metastatic melanoma positive BRAF V600 mutation , malignant tumor type harbor V600-activating mutation BRAF participant acceptable standard treatment option .</brief_summary>
	<brief_title>A Study Investigate Effect Itraconazole Rifampin Pharmacokinetics ( PK ) Vemurafenib Steady State</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Participants age great equal ( &gt; = ) 18 year either unresectable Stage IIIC Stage IV metastatic melanoma positive BRAF V600 mutation , malignant tumor type harbor V600activating mutation BRAF Eastern Cooperative Oncology Group Performance Status 0 2 Life expectancy &gt; =12 week Adequate hematologic end organ function obtain within 2 week prior first dose study drug Female participant childbearing potential male participant partner childbearing potential must agree always use two effective method contraception include least one method failure rate &lt; 1 % per year course study least 6 month completion study treatment Negative serum pregnancy test within 7 day prior commencement dose woman childbearing potential Absence psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule Prior treatment vemurafenib BRAF inhibitor within 42 day Study Day 1 Period A Allergy hypersensitivity component vemurafenib formulation Experimental therapy within 4 week prior first dose study drug treatment Study Day 1 Period A Major surgical procedure significant traumatic injury within 14 day prior first dose study drug treatment Study Day 1 Period A , anticipation need major surgery study treatment Prior anticancer therapy ( e.g. , biologic target therapy , chemotherapy ) within 28 day ( 6 week nitrosoureas mitomycin C , 14 day hormonal therapy kinase inhibitor ) first dose study treatment Study Day 1 Period A .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>